M&A / Deals Teva makes its first M&A play in years, buying Emalex PharmaphorumTeva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolioNext: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
